Agilent
Technologies, Inc. (NYSE: A) and SomaLogic,
Inc. (a privately held biotechnology company) today announced a
multi-year supply agreement whereby Agilent will supply customized
high-fidelity oligo microarrays for use in the nucleic acid detection
step within SomaLogic’s novel SOMAscan
assay, a protein measurement platform with applications across basic
and clinical research, diagnostics, and pharmaceutical discovery and
development.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190430005105/en/
SomaLogic’s SOMAscan assay solves a protein measurement challenge using
a DNA measurement solution, enabling the accurate measurement of an
individual’s protein makeup with unequalled sensitivity and dynamic
range. The customized Agilent microarray, which is based on SomaLogic’s
specifications, is incorporated into the SOMAscan assay which is used to
detect and measure 5,000 proteins accurately and reproducibly from a
small volume of biological sample.
“Agilent and SomaLogic have developed a mutually rewarding partnership
over the years, and we are pleased that they will continue to leverage
our microarray platform as they scale up their business,” said Sam Raha,
president of Agilent’s Diagnostics and Genomics Group. “Agilent’s
microarray platform has demonstrated superiority for measurement of DNA
and RNA at scale and it is exciting to see how SomaLogic is creatively
applying this capability to measure thousands of proteins in a single
assay.”
“To date we have analyzed over 300,000 human samples as we have built
the SOMAscan platform,” said Roy Smythe, CEO of SomaLogic. “Agilent
custom microarrays have been a critical part of our success to date, and
as we now move into health, wellness and disease-monitoring applications
for our technology they continue to be an extremely high quality and
scalable solution.”
Specific details of the agreement were not disclosed.
About SomaLogic
SomaLogic seeks to deliver meaningful and actionable health-management
insights that empower individuals worldwide to continuously optimize
their personal health and wellness throughout their lives. These
essential insights, to be provided through a global network of partners
and users, are derived from the precise, proprietary, and personalized
measurement of critical changes in an individual’s proteins over time.
For more information, visit www.somalogic.com
and follow @somalogic on Twitter.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to customers’ most
challenging questions. The company generated revenues of $4.91 billion
in fiscal 2018 and employs 15,300 people worldwide. Information about
Agilent is available at www.agilent.com.
To receive the latest Agilent news, subscribe to our Newsroom.
Follow Agilent on LinkedIn,
Twitter,
and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190430005105/en/